Detalhe da pesquisa
1.
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer.
BJU Int
; 130(5): 592-603, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34597472
2.
Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
Prostate
; 81(7): 427-432, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33760238
3.
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
Prostate
; 81(7): 433-439, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792945
4.
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
BJU Int
; 128(2): 196-205, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33556233
5.
Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Cancer
; 126(6): 1208-1216, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31829450
6.
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
J Urol
; 204(1): 63-70, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31971495
7.
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Clin Genitourin Cancer
; 20(6): 558-567, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36155169
8.
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
Clin Genitourin Cancer
; 20(2): 165-175, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35078711
9.
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Clin Genitourin Cancer
; 20(5): e440-e452, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35778337
10.
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
Eur Urol Oncol
; 4(3): 464-472, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33423945
11.
Inherited DNA-repair gene mutations in African American men with prostate cancer.
Oncotarget
; 11(4): 440-442, 2020 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32064047
12.
Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer.
Oncotarget
; 11(1): 15-21, 2020 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32002120
13.
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.
Cancer Treat Res Commun
; 24: 100193, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32702615
14.
TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
Clin Genitourin Cancer
; 18(2): 148-154, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31822380
15.
Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer.
JCO Precis Oncol
; 32019.
Artigo
em Inglês
| MEDLINE | ID: mdl-32914020